Holen Sie sich die Stockscreener-App
6.68
1.33%
-0.09
Schlusskurs vom Vortag:
$6.77
Offen:
$6.8
24-Stunden-Volumen:
1.80M
Relative Volume:
0.65
Marktkapitalisierung:
$724.07M
Einnahmen:
$42.51M
Nettoeinkommen (Verlust:
$-116.49M
KGV:
-5.9643
EPS:
-1.12
Netto-Cashflow:
$-120.82M
1W Leistung:
+13.03%
1M Leistung:
+29.46%
6M Leistung:
+116.88%
1J Leistung:
-32.46%
1-Tages-Spanne:
$6.36
$6.85
1-Wochen-Bereich:
$5.90
$7.14
52-Wochen-Spanne:
$1.03
$12.02
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Vergleichen Sie TNGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
6.68 | 640.61M | 42.51M | -116.49M | -120.82M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
What analysts say about Tango Therapeutics Inc. stockTremendous growth potential - jammulinksnews.com
Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 - GlobeNewswire
What drives Tango Therapeutics Inc. stock priceFree Consultation - jammulinksnews.com
Is Tango Therapeutics Inc. a good long term investmentFree Popular Stock Recommendations - jammulinksnews.com
Will Tango Therapeutics Inc. stock benefit from interest rate changesMarket Timing Advice - Newser
How Tango Therapeutics Inc. stock performs during market volatilityFree Consultation - Newser
Tango Therapeutics Inc. Stock Analysis and ForecastAccelerated financial growth - jammulinksnews.com
How high can Tango Therapeutics Inc. stock price go in 2025Daily Volume Leaders - Newser
Can Tango Therapeutics Inc Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect? - MSN
What makes Tango Therapeutics Inc. stock price move sharplySolid Return Trade Selections - Newser
Why Tango Therapeutics Inc. stock attracts strong analyst attentionFree Capital Growth Strategies - Newser
Tango Therapeutics (TNGX) Soars 5.96% on Strong Q2 Earnings - AInvest
Tango Therapeutics’ SWOT analysis: biotech stock’s potential in precision cancer therapies - Investing.com
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? - MSN
HC Wainwright Issues Optimistic Forecast for TNGX Earnings - Defense World
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 3000 Value Index - MarketScreener
H.C. Wainwright reiterates Buy rating on Tango Therapeutics stock - Investing.com
Tango Therapeutics Announces First Patient Dosed in Phase - GlobeNewswire
Tango Therapeutics Launches Groundbreaking Trial for Advanced Pancreatic and Lung Cancer Treatment - Stock Titan
Exchange Traded Concepts LLC Purchases 47,901 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics' Mysterious 7.5% Spike: What’s Behind the Move? - AInvest
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Tango Therapeutics’ SWOT analysis: stock poised for growth amid clinical trials - Investing.com
Two Sigma Investments LP Sells 23,166 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
B. Riley Increases Earnings Estimates for Tango Therapeutics - Defense World
What is B. Riley’s Forecast for TNGX Q2 Earnings? - Defense World
Squarepoint Ops LLC Makes New $40,000 Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Two Sigma Advisers LP Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock Holdings Increased by Bank of America Corp DE - Defense World
11,198 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Acquired by Ameriprise Financial Inc. - Defense World
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):